Month: July 2020

FDA Expands Enforcement Discretion Policy for Certain Regenerative Medicine Products

Read the article The United States Food and Drug Administration extends the Enforcement Discretion Policy for certain Cell, Tissue, and Human Cell and Tissue (HCT / P) products. Due to the challenges presented by the COVID-19 public health emergency, the…